Skip to main content
. 2013 Apr 16;4(5):677–690. doi: 10.18632/oncotarget.952

Figure 6. Opioid receptor activation by D,L-methadone inhibits growth of leukemia xenografts and increases doxorubicin sensitivity in vivo.

Figure 6

Fragments of an in vivo passage of a patient-derived T-ALL (ALL-SCID6, see also Figure 1) were transplanted into male NSG mice. Mice were treated with D,L-methadone alone (n=8, orally day 1-76, D,L-Methadone), with doxorubicin alone (n=8, i.v. day 46,53,60,76, Doxorubicin) or with a combination treatment with D,L-methadone and doxorubicin (n=8, D,L-Methadone + Doxorubicin). D,L-Methadone was used in weekly increasing doses from 20 up to 120mg/kg/day and doxorubicin in a dose of 3mg/kg. As control group xenografted mice were treated i.v. with 10% Tween 80 in saline (n=8, Vehicle). For 76 days after transplantation all mice were monitored for tumor growth, body weight and health condition. *significant to vehicle (p<0.05, Mann-Whitney U test).